J B Chemicals & Pharmaceuticals (JB Pharma) is a pharmaceutical company that makes branded generic medicines, active pharmaceutical ingredients (APIs), and contract-manufactured lozenges for some of the world’s largest consumer-health companies. Founded in 1976 by Mr. J. B. Mody, it launched household Indian brands like Nicardia, Rantac, and Metrogyl within its first decade, and over nearly fifty years grew into a diversified business with a presence in over 40 countries and a top-5 global position in medicated lozenges. The recurring approach that explains the company is a focus on chronic therapies and durable brand franchises, scaled through a series of targeted acquisitions - a strategy that was accelerated after private-equity firm KKR took a controlling stake in 2020, and which culminated in Torrent Pharmaceuticals acquiring that stake and initiating a full amalgamation of JB Pharma in 2026. # Business segments A single pharmaceutical engine with four mutually reinforcing streams - a domestic branded-formulations anchor, an international generics arm, a global lozenges CDMO, and a captive API unit - all running on shared manufacturing and R&D infrastructure. ## 1. Domestic branded formulations: the prescription engine that carries the house **A field force of over 2,600 medical representatives takes six mega-brands and a growing chronic-therapy portfolio to nearly 345,000 doctors, consistently growing faster than the Indian pharmaceutical market.** - **Chronic therapies provide half the revenue** - cardiology, gastroenterology, and nephrology products account for 50% of domestic sales, and this chronic portfolio grew at 19% in FY26, outpacing the industry’s 14%. - **Six brands each cross INR 100 crores** - the Cilacar franchise (hypertension) leads at INR 520 crores in value sales, followed by Rantac (anti-ulcer, INR 340 crores), Nicardia (hypertension, INR 245 crores), Metrogyl (amoebicide, INR 235 crores), the Sporlac probiotic franchise (INR 133-160 crores), and the Razel cholesterol franchise (over INR 100 crores); together they contribute more than half of domestic formulations revenue. - **Dominant market shares in legacy brands** - Metrogyl commands an 82% share of its category, Nicardia holds 93%, and Rantac has 41%, with Rantac and Metrogyl among the top 10 most prescribed brands in the country. - **Bought, not just built** - the ophthalmology portfolio (INR 230 crores in sales, promoted by a dedicated 100-person field force) was acquired via a perpetual trademark license from Novartis, the paediatric range including Z&D came from Dr. Reddy’s, the Azmarda heart-failure brand from Novartis, and the Razel franchise from Glenmark, expanding the brand basket from five meaningful contributors in 2021 to eighteen by 2025. - **Productivity has nearly doubled** - per-capita field-force output rose from INR 3.6 lakhs per month in FY20 to INR 8.0 lakhs in FY25, as the go-to-market model was reorganised into therapy-focused divisions targeting cardiologists, consulting physicians, and paediatricians. ## 2. International formulations: a three-hub export network with a niche US leg **Branded generics sold through wholly-owned subsidiaries in Russia and South Africa, plus a distributor-led model across 40 other countries, with an asset-light US generics business that leans on captive API supply.** - **Russia is a three-decade brand play** - the subsidiary OOO Unique Pharmaceutical Laboratories markets around 10 prescription brands through an 80-person sales force, with established pharmacy relationships and brand equity built over 30 years, particularly in the over-the-counter segment. - **South Africa shifted from tenders to retail** - Biotech Laboratories, ranked #15 by value and #11 by volume, has deliberately reduced low-margin public-tender exposure from 60% of its business in FY21 to 30%, growing the higher-margin private pharmacy channel to 70%. - **The US model is low-risk and cost-plus** - the company holds 15 approved ANDAs and sells low-volume, high-value generics like Glipizide and Carbamazepine through distributors, with margins protected by backward integration into the API that goes into those same drugs. - **Rest-of-world runs through local distributors** - across Sub-Saharan Africa, Latin America, Southeast Asia, and the Middle East, the company supplies branded generics without building its own sales forces, while newer direct fronts in the UAE and Philippines are being established through subsidiaries. ## 3. CDMO: the world’s lozenge factory **A dedicated, fully automated plant in Daman makes roughly a billion lozenges a year for marquee consumer-health companies - a top-5 global position built on two decades of partner relationships.** - **Partners own the brand, JB Pharma owns the plant** - the company develops and manufactures medicated and herbal lozenges for multinationals like Procter & Gamble (Vicks, outside India), Reckitt (Strepsils), and Johnson & Johnson (Russia), who then commercialise them through their own global distribution networks. - **Capacity is built for scale** - the Kadaiya facility can produce 2 billion lozenges annually and currently runs at about half that, with EU GMP, ANVISA, SAHPRA, TGA, and EAEU accreditations that open access to regulated markets worldwide. - **New formats stretch beyond cough and cold** - the pipeline includes melatonin lozenges for sleep, immunity lozenges already launched in three European countries, and products for oral thrush and motion sickness, offered in centre-filled, powder-filled, and multiple flavour variants. - **Relationships span decades** - some client partnerships have run for twenty to thirty years, and because new lozenge projects involve lengthy product matching and partner research, the gestation period is high, creating a natural barrier to switching. ## 4. API: the backward-integration anchor **A US FDA-accredited plant at Panoli makes active pharmaceutical ingredients, led by a global leadership position in Diclofenac, while supplying key raw materials to the company’s own US generics business.** - **Among the world’s largest in Diclofenac** - the API business holds a leading position in the global market for this non-steroidal anti-inflammatory drug, alongside other products like Ciprofloxacin HCl and Meclizine HCl. - **Captive supply de-risks the US generics business** - backward integration into APIs such as Glipizide means the company makes the active ingredient that goes into its own US finished-dosage products, insulating margins from supplier pricing. - **Regulatory standing is clean** - the Panoli API facility holds approvals from the US FDA, MOH Japan, MOH Korea, and ANVISA Brazil, and its most recent US FDA inspection in March 2025 concluded with no observations and no Form 483 issued. # Manufacturing and R&D backbone **Eight formulation plants in Gujarat, 25-plus global regulatory accreditations, and proprietary controlled-release technology platforms supply every segment from a single manufacturing base.** - **Multi-dosage capacity with headroom** - the plants produce tablets, capsules, liquids, lozenges, creams, ointments, injectables, eye drops, and IV infusions, with overall utilisation at roughly 60-70%, leaving room for growth without major new capital expenditure. - **OROS technology sets the complex-drug capability** - JB Pharma is among the few Indian companies to implement osmotic-controlled release oral drug delivery, a system that uses a laser-drilled tablet to release medicine steadily over 24 hours, alongside other platforms like multi-layer tabletting, Wurster coating, and floating drug delivery. - **Regulatory approvals open global doors** - the facilities carry accreditations from the US FDA, EU GMP, SAHPRA (South Africa), TGA (Australia), Health Canada, and ANVISA (Brazil), among others, and both the T20 formulations plant and the D9 API plant passed US FDA inspections in March 2025 with zero observations. - **Supply chain is local and pre-positioned** - nearly two-thirds of procurement spend is with Indian suppliers, and raw materials are pre-positioned to ensure uninterrupted production for key domestic brands. # Group structure and partners **Torrent Pharmaceuticals is now the controlling promoter, having acquired KKR’s stake in January 2026, with a full amalgamation of JB Pharma into Torrent already sanctioned by the NCLT.** - **Torrent holds 48.80% and is merging the company** - Torrent acquired the stake from Tau Investment Holdings (the KKR entity that had held roughly 54% since 2020) and certain employees; a Scheme of Amalgamation was approved by shareholders and sanctioned by the NCLT Ahmedabad Bench in July 2026, under which JB Pharma will be absorbed as a going concern. - **Four wholly-owned international subsidiaries** - Biotech Laboratories in South Africa, OOO Unique Pharmaceutical Laboratories in Russia, Unique Pharmaceutical Laboratories FZE in Dubai, and JBCPL Philippines Inc. (a step-down subsidiary incorporated in April 2024) carry the international branded-generics business. - **Key brand acquisitions came from global and domestic players** - the ophthalmology portfolio was licensed perpetually from Novartis for USD 116 million, the Azmarda brand from Novartis for USD 32.5 million, paediatric brands from Dr. Reddy’s for INR 98.3 crores, the Razel franchise from Glenmark, and probiotic brands from Sanzyme for INR 628 crores. - **CDMO partnerships are long-tenured** - manufacturing relationships with Procter & Gamble, Reckitt, Johnson & Johnson, and Inova span two to three decades and form the customer base for the lozenges CDMO business.